Interaction of BDNF with cytokines in chronic schizophrenia

Zhang, Xiang Yang; Tan, Yunlong; Chen, Dachun; Tan, Shuping; Yang, Fude; Wu, Hanjing Emily; Zunta-Soares, Giovana; Huang, Xu‐Feng; Kosten, Thomas R.; Soares, Jair C.

doi:10.1016/j.bbi.2015.09.014

Cited by 69 publications

(30 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One such immune molecule increased in the MIA offspring later in development is the proinflammatory cytokine TNF α . Increased levels of TNF α has been found in both ASD ( Chez et al , 2007 ; Vargas et al , 2005 ) and SZ ( Miller et al , 2011 ) although reduction in TNF α levels was also reported in SZ ( Zhang et al , 2016 ). Impaired TNF α signaling has been implicated in impaired neurogenesis during maternal infections ( Carpentier et al , 2011 ).…”

Section: Discussionmentioning

confidence: 96%

Maternal Immune Activation Causes Behavioral Impairments and Altered Cerebellar Cytokine and Synaptic Protein Expression

Pendyala

Chou

Jung

et al. 2017

Neuropsychopharmacol

View full text Add to dashboard Cite

Emerging epidemiology studies indicate that maternal immune activation (MIA) resulting from inflammatory stimuli such as viral or bacterial infections during pregnancy serves as a risk factor for multiple neurodevelopmental disorders including autism spectrum disorders and schizophrenia. Although alterations in the cortex and hippocampus of MIA offspring have been described, less evidence exists on the impact on the cerebellum. Here, we report altered expression of cytokines and chemokines in the cerebellum of MIA offspring, including increase in the neuroinflammatory cytokine TNFα and its receptor TNFR1. We also report reduced expression of the synaptic organizing proteins cerebellin-1 and GluRδ2. These synaptic protein alterations are associated with a deficit in the ability of cerebellar neurons to form synapses and an increased number of dendritic spines that are not in contact with a presynaptic terminal. These impairments are likely contributing to the behavioral deficits in the MIA exposed offspring.

show abstract

Section: Discussionmentioning

confidence: 96%

Maternal Immune Activation Causes Behavioral Impairments and Altered Cerebellar Cytokine and Synaptic Protein Expression

Pendyala

Chou

Jung

et al. 2017

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Second, we did not analyze the influence of inflammation on the correlation between BDNF and schizophrenia. Some studies reported that interactions between inflammatory factors and BDNF may be implicated in the pathophysiology and cognitive impairment seen in chronic schizophrenia [43, 44]. Therefore, an as yet unknown interaction between inflammatory factors and BDNF in DS may be an avenue worth researching further.…”

Section: Discussionmentioning

confidence: 99%

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

et al. 2019

View full text Add to dashboard Cite

Background To measure the serum levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in deficit schizophrenia (DS), in order to examine the association between these two neurotrophic factors (NFs) and cognitive performance. Methods A total of 109 male patients [51 DS and 58 non-deficit schizophrenia (NDS)] with schizophrenia and 40 sex and age matched healthy controls (HC) participated in this study. Processing speed, attention, executive function, and working memory of all subjects were assessed by means of a battery of classical neuropsychological tests. Serum BDNF and GDNF levels were measured simultaneously using a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Results There were significant differences in the overall cognitive test scores between three groups (all p < 0.001). Serum BDNF levels were significantly lower in patients (DS and NDS) than in HC ( p < 0.001). Furthermore, BDNF levels were lower in the DS compared to the NDS group, although not significantly. However, there was no difference in the GDNF levels between patients (DS and NDS) and HC. GDNF levels were positively correlated with scores of Stroop words only ( r = 0.311, p = 0.033), Stroop colors only ( r = 0.356, p = 0.014) and Stroop interference ( r = 0.348, p = 0.016) in DS group . Conclusion Serum BDNF may be an unsuitable biomarker for DS, despite a significant decrease in schizophrenia patients. The different neurocognitive performance between the DS and NDS patients indicates that DS may be a separate clinical entity of schizophrenia. Finally, higher serum GDNF levels are associated with better cognitive performance in DS patients, indicating a possible neuroprotective function in DS.

show abstract

“…Additionally, serum brain-derived neurotrophic factor (BDNF) levels are positively associated with cognitive functions, such as immediate memory, in chronic schizophrenia patients ( 4 ). In addition, Zhang et al ( 5 ) found that low BDNF levels are associated with poor performance on the cognitive factor of the Positive and Negative Syndrome Scale (PANSS) in chronic schizophrenia. In particular, Tumor Necrosis Factor-α (TNF-α) may interact with BDNF and cause cognitive impairment.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients

et al. 2018

View full text Add to dashboard Cite

Background: Cognitive impairment in schizophrenia can result in considerable difficulty in performing functions of daily life or social rehabilitation. Cognitive impairment in schizophrenia is related to various factors, such as the psychotic severity, aging, medication, and brain-derived neurotrophic factor (BDNF). To date, however, no studies investigating the impact of these factors on cognitive functioning in chronic schizophrenia patients have been performed.Objective: The aim of this study is to identify those factors that influence the cognitive functioning in patients with chronic schizophrenia.Methods: Sixty-five of 116 long-term hospitalized chronic schizophrenia patients (63.8 ± 12.1 years old, M/F = 29/36) were enrolled this cross-sectional study. We investigated the relationship among the patients' age, psychotic severity, treatment medication, serum BDNF levels, and cognitive functioning (measured by the Japanese-language version of the Brief Assessment of Cognition in Schizophrenia; BACS-J). Additionally, we performed a multivariable linear regression analysis.Results: According to the partial correlation analysis, certain parameters [i.e., age, chlorpromazine (CP) equivalent, biperiden (BP) equivalent, and serum BDNF] were significantly correlated with cognitive functioning, including working memory (WM), motor function (MF), attention and processing speed (AP), and executive function (EF). For the multivariate analysis, the MF component, which had the highest correlation, was selected as the dependent variable, and the independent variables included age, Manchester Scale for chronic psychosis (ManS) total score, CP equivalent, BP equivalent, serum BDNF, estimated full scale IQ, and years of education. According to the multiple regression analysis of this model, R (multiple regression coefficient) was 0.542, the adjusted R2 (coefficient of determination) was 0.201, and only BP equivalent (β = −0.305, p = 0.030), but not age, ManS score, CP equivalent, or serum BDNF, could significantly explain MF at the 5% significant level.Conclusion: In conclusion, aging, medication (administering more antipsychotics or anticholinergics), and serum BDNF concentration are significantly correlated with cognitive dysfunction in chronic schizophrenia patients but not with the severity of psychotic symptoms. Furthermore, only the anticholinergic dosage had a significant causal relationship with MF. Thus, the use of anticholinergics in chronic schizophrenia patients with deteriorating cognitive functioning must be reconsidered.

show abstract

Interaction of BDNF with cytokines in chronic schizophrenia

Cited by 69 publications

References 72 publications

Maternal Immune Activation Causes Behavioral Impairments and Altered Cerebellar Cytokine and Synaptic Protein Expression

Maternal Immune Activation Causes Behavioral Impairments and Altered Cerebellar Cytokine and Synaptic Protein Expression

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients

Contact Info

Product

Resources

About